SCHEMBL5584288

SCHEMBL5584288

CCOC(=O)c1cc2c(OCc3ccccc3)cccc2n1CC(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
TSHR P16473 2/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
F10 P00742 3/20 0.46
LMNA P02545 3/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NOD2 Q9HC29 1/20 0.43
NOD1 Q9Y239 1/20 0.43
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PPIA P62937 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL702060 0.89 F10 (0.48) MAPTTSHRALDH1A1POLBATM
SCHEMBL4997665 0.84 SRD5A2 (0.47) MAPTTSHRALDH1A1TDP1LMNA
SCHEMBL6433663 0.81 F10 (0.50) MAPTTSHRALDH1A1POLBATM
SCHEMBL5584948 0.80 F10 (0.47) MAPTTSHRALDH1A1POLBATM
SCHEMBL914147 0.78 TRPV3 (0.48) MAPTPOLBATMLMNAKDM4E
SCHEMBL699903 0.77 F10 (0.48) MAPTTSHRALDH1A1POLBATM
SCHEMBL9788508 0.73 MEN1 (0.51) POLBLMNAKMT2AMEN1PPIA
SCHEMBL5005325 0.73 SRD5A2 (0.61) MAPTTDP1KMT2AMEN1MAPK1
SCHEMBL7877768 0.72 SRD5A2 (0.52) MAPTTSHRALDH1A1TDP1LMNA
SCHEMBL6797552 0.72 KDM4E (0.49) MAPTALDH1A1TDP1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A MAPT 949/4885TSHR 1072/4885ALDH1A1 443/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A MAPT 949/4885TSHR 1072/4885ALDH1A1 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.